Novel treatments and future perspectives: Outcomes of intrathecal drug delivery

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Dickson, P I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Blood brain barrier; Enzyme replacement therapy; Intrathecal; Lysosomal storage disease; Mucopolysaccharidoses

Indexed keywords

LYSOSOMAL PROTEINS; PROTEIN; RECOMBINANT PROTEIN;

ANIMAL; BRAIN; DEGENERATIVE DISEASE; DISEASE MODEL; ENZYME REPLACEMENT; ENZYMOLOGY; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; LYSOSOME STORAGE DISEASE; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; HUMANS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; LYSOSOMAL STORAGE DISEASES; NEURODEGENERATIVE DISEASES; PROTEINS; RECOMBINANT PROTEINS;

EID: 77649219162     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr. 2001; 138: 539-547. (Pubitemid 32319728)
2. Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des. 2008; 14: 1566-1580. (Pubitemid 352002984)
3. Belichenko PV, Dickson PI, Passage M, Jungles S, Mobley WC, Kakkis ED. Penetration, diffusion, and uptake of recombinant human α-L-iduronidase after intraventricular injection into the rat brain. Mol Genet Metab. 2005; 86: 141-149. (Pubitemid 41412170)
4. Boelens JJ, Wynn RF, O'Meara A, Veys P, Bertrand Y, Souillet G et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007; 40: 225-233. (Pubitemid 47108465)
5. Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2007; 19: 628-635. (Pubitemid 350145229)
6. Chang M, Cooper JD, Sleat DE, Cheng SH, Dodge JC, Passini MA et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther. 2008; 16: 649-656. (Pubitemid 351426165)
7. Dickson P, McEntee M, Vogler C, Le S, Levy B, Peinovich M et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab. 2007a; 91: 61-68. (Pubitemid 46550919)
8. Dickson P, Naylor D, Mlikotic A, Victoroff A, Chen A, Passage M et al. Intrathecal recombinant human α-L-iduronidase alleviates spinal cord compression symptoms and is well tolerated in attenuated MPS I patients. Mol Genet Metab. 2007b; 93: 247(abstract).
9. Enns GM, Huhn SL. Central nervous system therapy for lysosomal storage disorders. Neurosurg Focus. 2008; 24: E12.
10. Garcia AR, Pan J, Stronge A, Tonini M, Alessandrini M, Neal C et al. Intrathecal delivery of iduronate 2-sulfatase to the CNS of cynomolgous monkeys. American Society of Human Genetics 57th Annual Meeting, San Diego, CA, USA; 2007 (abstract).
11. Giugliani R, Horovitz D, Jardim L, Costa R, Fagondes S, Viera T et al. Treating symptomatic spinal cord compression with intrathecal enzyme therapy in three Bralizian patients with MPS: what has happened so far. American Society of Human Genetics 57th Annual Meeting, San Diego, CA, USA; 2007 (abstract).
12. Hemsley KM, King B, Hopwood JJ. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol Genet Metab. 2007; 90: 313-328.
13. Jeyakumar M, Butters TD, Dwek RA, Platt FM. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol. 2002; 28: 343-357. (Pubitemid 35279069)
14. Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004; 83: 163-174. (Pubitemid 39328075)
15. Lee WC, Tsoi YK, Troendle FJ, DeLucia MW, Ahmed Z, Dicky CA et al. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 2007; 21: 2520-2527. (Pubitemid 47230681)
16. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract. 2007; 61: 293-302.
17. Miranda SR, He X, Simonaro CM, Gatt S, Dagan A, Desnick RJ et al. Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEBJ. 2000; 14: 1988-1995.
18. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3421-3452.
19. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003; 31: 229-239. (Pubitemid 36336225)
20. Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr. 2008; 97 (Suppl 457): 88-93. (Pubitemid 351421298)
21. Priller J, Flugel A, Wehner T, Boentert M, Haas CA, Prinz M et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med. 2001; 7: 1356-1361. (Pubitemid 34007942)
22. Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs. 2007; 67: 2697-2716. (Pubitemid 350224380)
23. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007; 25: 1350-1356. (Pubitemid 46706881)
24. Shinoura N, Tabei Y, Yamada R, Saito K, Takahashi M. Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. J Neurooncol. 2008; 87: 309-316.
25. Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H. Intrathecal drug delivery. Pain Physician. 2008; 11: 89-104.
26. Stapleton S, Blaney S. New agents for intrathecal administration. Cancer Invest. 2006; 24: 528-534. (Pubitemid 44576407)
27. Swanson PD. Diagnosis of inherited metabolic disorders affecting the nervous system. J Neurol Neurosurg Psychiatry. 1995; 59: 460-470.
28. Tolar J, Dickson P, Orchard P. Combined intrathecal iduronidase, intravenous iduronidase, and transplantation as therapy for Hurler syndrome. Mol Genet Metab. 2009; 96: S43 (abstract).